Reviva Pharmaceuticals Files 8-K

TL;DR

REVIVA files 8-K for corporate changes & financials.

AI Summary

Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on September 26, 2025, reporting amendments to its Articles of Incorporation or Bylaws and financial statements. The company, formerly Tenzing Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing indicates corporate updates and the submission of financial information, which are crucial for investors to understand the company's current status and compliance.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain information suggesting immediate financial distress or significant operational changes.

Key Players & Entities

• REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — Registrant
• Tenzing Acquisition Corp. (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• September 26, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share RVPH Nasdaq Capital Marke

Filing Documents

• rvph20250925_8k.htm (8-K) — 29KB
• ex_864375.htm (EX-3.1) — 4KB
• 0001437749-25-029951.txt ( ) — 182KB
• rvph-20250926.xsd (EX-101.SCH) — 4KB
• rvph-20250926_def.xml (EX-101.DEF) — 14KB
• rvph-20250926_lab.xml (EX-101.LAB) — 18KB
• rvph-20250926_pre.xml (EX-101.PRE) — 14KB
• rvph20250925_8k_htm.xml (XML) — 5KB

03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 26, 2025, the Board of Directors of Reviva Pharmaceuticals Holdings, Inc. (the "Company") approved and adopted, effective as of that date, an amendment (the "Amendment") to the Company's Bylaws, as originally adopted and effective as of December 11, 2020 (the "Bylaws"). The Amendment reduces the quorum at all meetings of the Company's stockholders for the transaction of business, except as otherwise required by law or by the Company's Amended and Restated Certificate of Incorporation, as amended, or Bylaws, to one-third (33%) of the voting power of the stock outstanding and entitled to vote at the meeting, present in person, present by remote communication, if applicable, or represented by proxy. The Bylaws previously provided that a majority in voting power of the shares entitled to vote at the meeting, present in person or represented by proxy, would constitute a quorum at all meetings of the Company's stockholders for the transaction of business. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 3.1 hereto and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 3.1 Amendment No. 1, as adopted and approved by the Board of Directors on September 26, 2025, to the Bylaws of Reviva Pharmaceuticals Holdings, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVIVA PHARMACEUTICALS HOLDINGS, INC. Date: September 26, 2025 By: /s/ Narayan Prabhu Narayan Prabhu Chief Financial Officer